arrow
S

Suresh S. Ramalingam

Emory University
H指数:124
被引数:10.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery

LAURA研究结果的大众化解读:对于EGFR突变型非小细胞肺癌患者,在无法手术切除的情况下,化疗放疗后的奥希替尼治疗

2026-04-270
OA
Exposed phosphatidylserine is an inhibitory molecule in T cell exhaustion

暴露的磷脂酰丝氨酸是T细胞耗竭中的抑制性分子

Nature
IF48.5
2026-03-250
PRE
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

晚期实体瘤患者AXL特异性抗体药物偶联物Enapotamab Vedotin的I/II期研究

2025-11-010
OA
Exposed phosphatidylserine is a non-classical inhibitory molecule during CD8 T cell exhaustion

暴露的磷脂酰丝氨酸是CD8 T细胞耗竭期间的非经典抑制分子

2025-11-010
PRE
Non-canonical dihydrolipoyl transacetylase promotes chemotherapy resistance via mitochondrial tetrahydrofolate signaling

非经典二氢硫辛酰胺转乙酰酶通过线粒体四氢叶酸信号促进化疗耐药性

2025-10-080
OAAI
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

肺大细胞神经内分泌癌的整合分子与临床特征分析

2025-08-190
OA
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1

一线Nivolumab + Ipilimumab与CheckMate 227化疗治疗的转移性NSCLC患者6年以上的无治疗生存率

2025-06-030
PREAI
EGFR mutation testing across the osimertinib clinical program

奥希替尼临床项目中的EGFR突变检测

2025-06-010
PRE
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
2025-03-010
OAAI
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial

先前接受过Tarlatamab治疗的小细胞肺癌患者的患者报告结局: DeLLphi-301 2期试验的结果

2025-03-010
OAAI